Baxter Healthcare Corporation - - BioPharm International

ADVERTISEMENT

Baxter Healthcare Corporation

BioPharm International
Volume 19, Issue 12

Company Description



Baxter Healthcare Corporation's BioPharma Solutions business offers proprietary technologies and contract services, addressing outsourcing needs throughout development and commercialization of parenteral (injectable and pulmonary) drugs. The company has partnered with more than 150 clients, working with the top 15 biopharmaceutical companies.

Products and Services

Contract Services: Baxter provides a range of contract services from process development of biopharmaceutical active ingredients to form–fill–finish of drug product into syringes, vials, and cartridges. It also provides cytotoxic contract services from chemical synthesis (API) to scale-up for commercial production. With over 15 years of experience, we provide contract development and manufacturing services for antibodies and protein therapeutics. Our licensed facilities in Hayward and Thousand Oaks, California, have capacity for preclinical to commercial scale production.

Baxter's Bloomington facility has expanded capacities for syringe and vial filling–finishing; and has added new capability in cartridge filling–finishing as well as a fully automated kitting line. Lyophilization capacity has increased along with the establishment of the Lyophilization Center of Excellence. Baxter can also provide analytical and microbiological services as well as validation and regulatory assistance.

Proprietary Formulation Technologies: NANOEDGE dispersion technology offers innovative formulations for solubility challenges and is applicable to multiple routes of administration. It reduces the particle size of most drugs to nanometer size, which can enhance a drug's saturation solubility and dissolution rate. It also eliminates the need for undesirable cosolvents and can offer higher drug loading and subsequent lower dose volume.

The PROMAXX microsphere technology is a unique, elegant, and cost effective formulation platform, tailored to fit specific requirements. It is applicable to a broad range of molecules— from small molecules and nucleic acids to peptides and proteins. PROMAXX technology can offer high drug loading and precise particle-size control and enable dosing flexibility across various administration routes, such as injectable and pulmonary with various drug release profiles such as immediate- and sustained-release.



Enhanced Packaging: Baxter also offers ready-to-use and ready-to-mix systems that can help differentiate your molecule and simplify end-users' drug preparation and administration. An established franchise into critical care clinicians globally supports end-user acceptance and market presence.

BAXTER HEALTHCARE CORPORATION
PO Box 3068
927 S. Curry Pike
Bloomington, IN 47403

TELEPHONE
800.353.0887
812.333.0887

FAX
812.332.3079

EMAIL

WEB ADDRESS
http://www.baxterdrugdelivery.com/

EMPLOYEES
600

FOUNDED
1991

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here